Cargando…

Transmitted/Founder and Chronic Subtype C HIV-1 Use CD4 and CCR5 Receptors with Equal Efficiency and Are Not Inhibited by Blocking the Integrin α4β7

Sexual transmission of human immunodeficiency virus type 1 (HIV-1) most often results from productive infection by a single transmitted/founder (T/F) virus, indicating a stringent mucosal bottleneck. Understanding the viral traits that overcome this bottleneck could have important implications for H...

Descripción completa

Detalles Bibliográficos
Autores principales: Parrish, Nicholas F., Wilen, Craig B., Banks, Lauren B., Iyer, Shilpa S., Pfaff, Jennifer M., Salazar-Gonzalez, Jesus F., Salazar, Maria G., Decker, Julie M., Parrish, Erica H., Berg, Anna, Hopper, Jennifer, Hora, Bhavna, Kumar, Amit, Mahlokozera, Tatenda, Yuan, Sally, Coleman, Charl, Vermeulen, Marion, Ding, Haitao, Ochsenbauer, Christina, Tilton, John C., Permar, Sallie R., Kappes, John C., Betts, Michael R., Busch, Michael P., Gao, Feng, Montefiori, David, Haynes, Barton F., Shaw, George M., Hahn, Beatrice H., Doms, Robert W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364951/
https://www.ncbi.nlm.nih.gov/pubmed/22693444
http://dx.doi.org/10.1371/journal.ppat.1002686
_version_ 1782234611479216128
author Parrish, Nicholas F.
Wilen, Craig B.
Banks, Lauren B.
Iyer, Shilpa S.
Pfaff, Jennifer M.
Salazar-Gonzalez, Jesus F.
Salazar, Maria G.
Decker, Julie M.
Parrish, Erica H.
Berg, Anna
Hopper, Jennifer
Hora, Bhavna
Kumar, Amit
Mahlokozera, Tatenda
Yuan, Sally
Coleman, Charl
Vermeulen, Marion
Ding, Haitao
Ochsenbauer, Christina
Tilton, John C.
Permar, Sallie R.
Kappes, John C.
Betts, Michael R.
Busch, Michael P.
Gao, Feng
Montefiori, David
Haynes, Barton F.
Shaw, George M.
Hahn, Beatrice H.
Doms, Robert W.
author_facet Parrish, Nicholas F.
Wilen, Craig B.
Banks, Lauren B.
Iyer, Shilpa S.
Pfaff, Jennifer M.
Salazar-Gonzalez, Jesus F.
Salazar, Maria G.
Decker, Julie M.
Parrish, Erica H.
Berg, Anna
Hopper, Jennifer
Hora, Bhavna
Kumar, Amit
Mahlokozera, Tatenda
Yuan, Sally
Coleman, Charl
Vermeulen, Marion
Ding, Haitao
Ochsenbauer, Christina
Tilton, John C.
Permar, Sallie R.
Kappes, John C.
Betts, Michael R.
Busch, Michael P.
Gao, Feng
Montefiori, David
Haynes, Barton F.
Shaw, George M.
Hahn, Beatrice H.
Doms, Robert W.
author_sort Parrish, Nicholas F.
collection PubMed
description Sexual transmission of human immunodeficiency virus type 1 (HIV-1) most often results from productive infection by a single transmitted/founder (T/F) virus, indicating a stringent mucosal bottleneck. Understanding the viral traits that overcome this bottleneck could have important implications for HIV-1 vaccine design and other prevention strategies. Most T/F viruses use CCR5 to infect target cells and some encode envelope glycoproteins (Envs) that contain fewer potential N-linked glycosylation sites and shorter V1/V2 variable loops than Envs from chronic viruses. Moreover, it has been reported that the gp120 subunits of certain transmitted Envs bind to the gut-homing integrin α4β7, possibly enhancing virus entry and cell-to-cell spread. Here we sought to determine whether subtype C T/F viruses, which are responsible for the majority of new HIV-1 infections worldwide, share biological properties that increase their transmission fitness, including preferential α4β7 engagement. Using single genome amplification, we generated panels of both T/F (n = 20) and chronic (n = 20) Env constructs as well as full-length T/F (n = 6) and chronic (n = 4) infectious molecular clones (IMCs). We found that T/F and chronic control Envs were indistinguishable in the efficiency with which they used CD4 and CCR5. Both groups of Envs also exhibited the same CD4+ T cell subset tropism and showed similar sensitivity to neutralization by CD4 binding site (CD4bs) antibodies. Finally, saturating concentrations of anti-α4β7 antibodies failed to inhibit infection and replication of T/F as well as chronic control viruses, although the growth of the tissue culture-adapted strain SF162 was modestly impaired. These results indicate that the population bottleneck associated with mucosal HIV-1 acquisition is not due to the selection of T/F viruses that use α4β7, CD4 or CCR5 more efficiently.
format Online
Article
Text
id pubmed-3364951
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-33649512012-06-12 Transmitted/Founder and Chronic Subtype C HIV-1 Use CD4 and CCR5 Receptors with Equal Efficiency and Are Not Inhibited by Blocking the Integrin α4β7 Parrish, Nicholas F. Wilen, Craig B. Banks, Lauren B. Iyer, Shilpa S. Pfaff, Jennifer M. Salazar-Gonzalez, Jesus F. Salazar, Maria G. Decker, Julie M. Parrish, Erica H. Berg, Anna Hopper, Jennifer Hora, Bhavna Kumar, Amit Mahlokozera, Tatenda Yuan, Sally Coleman, Charl Vermeulen, Marion Ding, Haitao Ochsenbauer, Christina Tilton, John C. Permar, Sallie R. Kappes, John C. Betts, Michael R. Busch, Michael P. Gao, Feng Montefiori, David Haynes, Barton F. Shaw, George M. Hahn, Beatrice H. Doms, Robert W. PLoS Pathog Research Article Sexual transmission of human immunodeficiency virus type 1 (HIV-1) most often results from productive infection by a single transmitted/founder (T/F) virus, indicating a stringent mucosal bottleneck. Understanding the viral traits that overcome this bottleneck could have important implications for HIV-1 vaccine design and other prevention strategies. Most T/F viruses use CCR5 to infect target cells and some encode envelope glycoproteins (Envs) that contain fewer potential N-linked glycosylation sites and shorter V1/V2 variable loops than Envs from chronic viruses. Moreover, it has been reported that the gp120 subunits of certain transmitted Envs bind to the gut-homing integrin α4β7, possibly enhancing virus entry and cell-to-cell spread. Here we sought to determine whether subtype C T/F viruses, which are responsible for the majority of new HIV-1 infections worldwide, share biological properties that increase their transmission fitness, including preferential α4β7 engagement. Using single genome amplification, we generated panels of both T/F (n = 20) and chronic (n = 20) Env constructs as well as full-length T/F (n = 6) and chronic (n = 4) infectious molecular clones (IMCs). We found that T/F and chronic control Envs were indistinguishable in the efficiency with which they used CD4 and CCR5. Both groups of Envs also exhibited the same CD4+ T cell subset tropism and showed similar sensitivity to neutralization by CD4 binding site (CD4bs) antibodies. Finally, saturating concentrations of anti-α4β7 antibodies failed to inhibit infection and replication of T/F as well as chronic control viruses, although the growth of the tissue culture-adapted strain SF162 was modestly impaired. These results indicate that the population bottleneck associated with mucosal HIV-1 acquisition is not due to the selection of T/F viruses that use α4β7, CD4 or CCR5 more efficiently. Public Library of Science 2012-05-31 /pmc/articles/PMC3364951/ /pubmed/22693444 http://dx.doi.org/10.1371/journal.ppat.1002686 Text en Parrish et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Parrish, Nicholas F.
Wilen, Craig B.
Banks, Lauren B.
Iyer, Shilpa S.
Pfaff, Jennifer M.
Salazar-Gonzalez, Jesus F.
Salazar, Maria G.
Decker, Julie M.
Parrish, Erica H.
Berg, Anna
Hopper, Jennifer
Hora, Bhavna
Kumar, Amit
Mahlokozera, Tatenda
Yuan, Sally
Coleman, Charl
Vermeulen, Marion
Ding, Haitao
Ochsenbauer, Christina
Tilton, John C.
Permar, Sallie R.
Kappes, John C.
Betts, Michael R.
Busch, Michael P.
Gao, Feng
Montefiori, David
Haynes, Barton F.
Shaw, George M.
Hahn, Beatrice H.
Doms, Robert W.
Transmitted/Founder and Chronic Subtype C HIV-1 Use CD4 and CCR5 Receptors with Equal Efficiency and Are Not Inhibited by Blocking the Integrin α4β7
title Transmitted/Founder and Chronic Subtype C HIV-1 Use CD4 and CCR5 Receptors with Equal Efficiency and Are Not Inhibited by Blocking the Integrin α4β7
title_full Transmitted/Founder and Chronic Subtype C HIV-1 Use CD4 and CCR5 Receptors with Equal Efficiency and Are Not Inhibited by Blocking the Integrin α4β7
title_fullStr Transmitted/Founder and Chronic Subtype C HIV-1 Use CD4 and CCR5 Receptors with Equal Efficiency and Are Not Inhibited by Blocking the Integrin α4β7
title_full_unstemmed Transmitted/Founder and Chronic Subtype C HIV-1 Use CD4 and CCR5 Receptors with Equal Efficiency and Are Not Inhibited by Blocking the Integrin α4β7
title_short Transmitted/Founder and Chronic Subtype C HIV-1 Use CD4 and CCR5 Receptors with Equal Efficiency and Are Not Inhibited by Blocking the Integrin α4β7
title_sort transmitted/founder and chronic subtype c hiv-1 use cd4 and ccr5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364951/
https://www.ncbi.nlm.nih.gov/pubmed/22693444
http://dx.doi.org/10.1371/journal.ppat.1002686
work_keys_str_mv AT parrishnicholasf transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT wilencraigb transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT bankslaurenb transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT iyershilpas transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT pfaffjenniferm transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT salazargonzalezjesusf transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT salazarmariag transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT deckerjuliem transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT parrishericah transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT berganna transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT hopperjennifer transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT horabhavna transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT kumaramit transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT mahlokozeratatenda transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT yuansally transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT colemancharl transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT vermeulenmarion transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT dinghaitao transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT ochsenbauerchristina transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT tiltonjohnc transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT permarsallier transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT kappesjohnc transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT bettsmichaelr transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT buschmichaelp transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT gaofeng transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT montefioridavid transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT haynesbartonf transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT shawgeorgem transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT hahnbeatriceh transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7
AT domsrobertw transmittedfounderandchronicsubtypechiv1usecd4andccr5receptorswithequalefficiencyandarenotinhibitedbyblockingtheintegrina4b7